| MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1 DS Rao, RM O'Connell, AA Chaudhuri, Y Garcia-Flores, TL Geiger, ... Immunity 33 (1), 48-59, 2010 | 287 | 2010 |
| Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens TL Geiger, MC Abt, G Gasteiger, MA Firth, MH O’Connor, CD Geary, ... Journal of Experimental Medicine 211 (9), 1723-1731, 2014 | 252 | 2014 |
| Transforming growth factor-β signaling guides the differentiation of innate lymphoid cells in salivary glands VS Cortez, L Cervantes-Barragan, ML Robinette, JK Bando, Y Wang, ... Immunity 44 (5), 1127-1139, 2016 | 223 | 2016 |
| Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin MA Curran, TL Geiger, W Montalvo, M Kim, SL Reiner, A Al-Shamkhani, ... Journal of Experimental Medicine 210 (4), 743-755, 2013 | 203 | 2013 |
| Development and maturation of natural killer cells TL Geiger, JC Sun Current opinion in immunology 39, 82-89, 2016 | 171 | 2016 |
| Non-viral precision T cell receptor replacement for personalized cell therapy SP Foy, K Jacoby, DA Bota, T Hunter, Z Pan, E Stawiski, Y Ma, W Lu, ... Nature 615 (7953), 687-696, 2023 | 112 | 2023 |
| Atg5 is essential for the development and survival of innate lymphocytes TE O’Sullivan, CD Geary, OE Weizman, TL Geiger, M Rapp, GW Dorn, ... Cell reports 15 (9), 1910-1919, 2016 | 71 | 2016 |
| Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy C Puig-Saus, B Sennino, S Peng, CL Wang, Z Pan, B Yuen, B Purandare, ... Nature 615 (7953), 697-704, 2023 | 50 | 2023 |
| NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’phenotypes that rapidly proliferate and kill target cells upon recognition of … B Sennino, A Conroy, B Purandare, A Litterman, K Jacoby, R Moot, W Lu, ... Cancer Research 79 (13_Supplement), 1433-1433, 2019 | 3 | 2019 |
| Highly efficient, non-viral precision genome engineering for the generation of personalized neoepitope-specific adoptive T cell therapies K Jacoby, R Moot, W Lu, D Nguyen, B Sennino, A Conroy, B Purandare, ... Cancer Research 79 (13_Supplement), 4783-4783, 2019 | 2 | 2019 |
| 1478 A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T … S Foy, K Jacoby, D Bota, T Hunter, A Schoenfeld, Z Pan, E Stawiski, Y Ma, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| 1202 In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology G Adams, F Soldevila, D Matsuda, Y Zhang, Y Bao, B Ross, SA Sievers, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Methods of determining gene editing eficiencies in cells K Jacoby, B Sennino, S Foy, TL Hunter US Patent App. 18/049,114, 2023 | | 2023 |
| Monitoring of neoantigens and adoptively transferred personalized neoTCR T cell populations in the tumor and PBMCs of patients with solid tumors S Foy, C Wang, B Yuen, S Said, B Quach, J Hoover, S Nayak, T Hunter, ... Cancer Research 83 (7_Supplement), 901-901, 2023 | | 2023 |
| 123 Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy CP Saus, B Sennino, S Peng, Z Pan, B Yuen, B Purandare, K Jacoby, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| DEVELOPMENTAL CONTROL OF INNATE LYMPHOID CELLS TL Geiger School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, 2016 | | 2016 |
| Regulation of virus-specific natural killer cell memory by IL-10 and TGF-β (CCR4P. 207) T Geiger, A Beaulieu, E Vivier, M Li, J Sun The Journal of Immunology 194 (1_Supplement), 118.7-118.7, 2015 | | 2015 |
| Systemic 4-1BB activation induces a novel T-cell phenotype driven by high expression of Eomesodermin (P2197) M Curran, T Geiger, W Montalvo, M Kim, S Reiner, A Al-Shamkhani, J Sun, ... The Journal of Immunology 190 (1_Supplement), 170.55-170.55, 2013 | | 2013 |
| Please let us know how this document benefits you. TE O'Sulivan, CD Geary, OE Weizman, TL Geiger, M Rapp, GW Dorn | | |
Eric VivierProfessor of Immunology, Aix-Marseille University & CSO Innate-PharmaDirección de correo verificada de ciml.univ-mrs.fr
